GlassScriptPhysician profile
Virat R Dave
NPI 1679512370
$6,207.38
in general payments reported to CMS, 2019-2025
35 companies · $1,069 in 2025
The $1,069 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $424 · 2020: $104 · 2021: $669 · 2022: $1,238 · 2023: $1,405 · 2024: $1,299 · 2025: $1,069.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,750 · Education: $22.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,750.43 |
| Education | $22.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,405.99 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $800.16 | 2020-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $374.33 | 2019-2025 | Entyvio, Eohilia |
| Daiichi Sankyo INC. | $306.79 | 2021-2023 | Injectafer |
| Pfizer INC. | $250.89 | 2019-2025 | |
| Janssen Biotech, INC. | $233.40 | 2021-2024 | Stelara, Remicade, Tremfya |
| Lilly USA, LLC | $195.14 | 2023-2025 | Omvoh |
| Qol Medical, LLC | $183.30 | 2019-2024 | Sucraid, Sucraid |
| Regeneron Healthcare Solutions, INC. | $176.92 | 2022-2025 | Dupixent |
| Enterra Medical, INC. | $151.15 | 2024-2025 | |
| Nestle Healthcare Nutrition INC. | $110.41 | 2022-2023 | |
| Redhill Biopharma INC. | $99.85 | 2021-2023 | Movantik, Aemcolo, Talicia |
| Ironwood Pharmaceuticals, INC | $95.38 | 2021-2024 | Linzess |
| Phathom Pharmaceuticals, INC. | $80.24 | 2025 | Voquezna |
| Celgene Corporation | $79.30 | 2021-2024 | Zeposia |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $62.91 | 2021-2023 | Amjevita, Avsola |
| Braintree Laboratories, INC. | $58.17 | 2023-2025 | Sutab, Suflave |
| Aimmune Therapeutics, INC. | $55.82 | 2024-2025 | Zenpep |
| Vivus LLC | $55.21 | 2022-2024 | Qsymia |
| Genzyme Corporation | $52.58 | 2024 | |
| Ardelyx, INC. | $48.79 | 2022-2023 | Ibsrela |
| Intercept Pharmaceuticals, INC. | $46.92 | 2019-2022 | |
| Allergan, INC. | $43.20 | 2019 | |
| Gilead Sciences, INC. | $31.67 | 2019 | |
| Ferring Pharmaceuticals INC. | $31.64 | 2019-2023 | Rebyota |
| Organon LLC | $27.06 | 2021-2024 | |
| Boston Scientific Corporation | $26.44 | 2022 | |
| Ethicon US, LLC | $20.54 | 2021 | |
| Evoke Pharma, INC. | $20.40 | 2023 | Gimoti |
| Laborie Medical Technologies Corp. | $18.57 | 2022 | |
| Fresenius Kabi USA, LLC | $17.54 | 2023 | Idacio |
| Merck Sharp & Dohme LLC | $16.38 | 2023 | Dificid |
| Celltrion USA INC. | $15.49 | 2025 | Vegzelma |
| Medtronic, INC. | $14.80 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$65,805.23 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Virat Dave listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.